Teijin collaborates with InCube Labs to boost health care business

22 January 2013

Japan’s Teijin (TYO: 3401) says it has signed a strategic partnership agreement with InCube Labs, a California-based life science research lab, to accelerate Teijin’s health care business development. Financial terms of the deal were not disclosed.

As part of the accord, Teijin will invest in a company affiliated with InCube Labs. By leveraging its extensive network and expertise, InCube Labs will help Teijin to define strategic growth opportunities for its health care business. Initiatives will include competitive evaluation of Teijin technologies, analysis of key market characteristics and regulations, and provision of information to help Teijin identify promising business partners and M&A opportunities.

Health care is one of the growth drivers in the Teijin group's medium-to-long-term management vision. The group plans to integrate its materials and health care technologies to facilitate its expansion into fields including regenerative medicine and tissue repair, drug delivery systems and locomotive syndrome.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK